Portfolio Sync Solutions
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTEDActual EPS
RedHill Biopharma Ltd. Analyst EPS Estimates
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|---|---|---|---|
| Q1 2025 | 1 | -$690.00 | -$690.00 | -$690.00 |
| Q2 2025 | 1 | -$137.50 | -$137.50 | -$137.50 |
| Q3 2025 | 1 | -$270.00 | -$270.00 | -$270.00 |
| Q4 2025 | 1 | -$346.00 | -$346.00 | -$346.00 |
| Q1 2026 | 1 | -$435.00 | -$435.00 | -$435.00 |
| Q2 2026 | 1 | -$352.86 | -$352.86 | -$352.86 |
| Q3 2026 | 1 | -$474.29 | -$474.29 | -$474.29 |
| Q4 2026 | 1 | -$433.33 | -$433.33 | -$433.33 |
| Q1 2027 | 1 | -$300.00 | -$300.00 | -$300.00 |
| Q2 2027 | 1 | -$20.00 | -$20.00 | -$20.00 |
| Q3 2027 | 1 | -$10.00 | -$10.00 | -$10.00 |
| Q4 2027 | 0 | $0.00 | $0.00 | $0.00 |
| Q1 2028 | 1 | -$20.00 | -$20.00 | -$20.00 |
| Q2 2028 | 1 | -$10.00 | -$10.00 | -$10.00 |
| Q3 2028 | 0 | $0.00 | $0.00 | $0.00 |
| Q4 2028 | 0 | $0.00 | $0.00 | $0.00 |
| Q1 2029 | 0 | $0.00 | $0.00 | $0.00 |
| Q2 2029 | 0 | $0.00 | $0.00 | $0.00 |
| Q3 2029 | 0 | $0.00 | $0.00 | $0.00 |
RedHill Biopharma Ltd. Earnings Date And Information
RedHill Biopharma Ltd. last posted its earnings results on Thursday, August 29th, 2024. The company reported $-200 earnings per share for the quarter, missing analysts' consensus estimates of $-30 by $170. The company had revenue of 1.80 M for the quarter and had revenue of 6.51 M for the year. RedHill Biopharma Ltd. has generated $4 earnings per share over the last year ($4 diluted earnings per share) and currently has a price-to-earnings ratio of 0. RedHill Biopharma Ltd. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, May 13th, 2025 based on prior year's report dates.
RedHill Biopharma Ltd. Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
|---|---|---|---|---|---|---|
| 08/17/2023 | Q2 2023 | N/A | $4.83 | N/A | $23.48 M | $1.80 M |
| 03/31/2023 | Q1 2023 | N/A | $20.44 | N/A | $22.75 M | $3.60 M |
| 04/28/2023 | Q4 2022 | N/A | $1.07 | N/A | $18.10 M | $12.80 M |
| 09/29/2022 | Q3 2022 | N/A | -$40.29 | N/A | $18.50 M | $17.55 M |
| 11/07/2022 | Q2 2022 | -$0.30 | -$10.04 | -9.74 | $21.50 M | $18.35 M |
| 03/17/2022 | Q1 2022 | -$400.00 | -$13.36 | 386.64 | $23.60 M | $18.24 M |
| 03/17/2022 | Q4 2021 | -$400.00 | -$19.65 | 380.35 | $24.09 M | $22.07 M |
| 09/29/2021 | Q3 2021 | N/A | -$18.28 | N/A | $24.51 M | $21.61 M |
| 06/30/2021 | Q2 2021 | N/A | -$24.95 | N/A | $24.29 M | $21.50 M |
| 05/27/2021 | Q1 2021 | -$460.00 | -$21.29 | 438.71 | $22.70 M | $20.58 M |
| 03/18/2021 | Q4 2020 | -$450.00 | -$25.69 | 424.31 | $26.04 M | $21.46 M |
| 09/29/2020 | Q3 2020 | N/A | -$19.99 | N/A | $25.36 M | $20.94 M |
| 06/29/2020 | Q2 2020 | N/A | -$17.95 | N/A | $22.99 M | $20.90 M |
| 03/04/2020 | Q1 2020 | -$320.00 | -$19.46 | 300.54 | $4.38 M | $1.06 M |
| 12/31/2019 | Q4 2019 | N/A | -$13.89 | N/A | $2.15 M | $1.59 M |
| 11/19/2019 | Q3 2019 | -$390.00 | -$13.87 | 376.13 | $1.79 M | $1.40 M |
| 05/07/2019 | Q2 2019 | -$390.00 | -$15.38 | 374.62 | $2.16 M | $1.56 M |
| 02/26/2019 | Q1 2019 | -$390.00 | -$13.92 | 376.08 | $2.76 M | $1.74 M |
| 11/13/2018 | Q4 2018 | -$400.00 | -$11.68 | 388.32 | N/A | $1.36 M |
| 08/30/2018 | Q3 2018 | -$470.00 | -$17.17 | 452.83 | N/A | $2.21 M |
Explore Related Stocks for Market Trends
Explore our related stocks for the latest market trends and stock news to stay informed and make better decisions.
RedHill Biopharma Ltd. Earnings: FAQ's
RedHill Biopharma Ltd. has not confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, May 13th, 2025 based offlast year's report dates.
The conference call for RedHill Biopharma Ltd.'s latest earnings report can be listened to online.
The conference call transcript for RedHill Biopharma Ltd.'s latest earnings report can be read online.
RedHill Biopharma Ltd. (:RDHL) has a recorded annual revenue of $6.51 M.
RedHill Biopharma Ltd. (:RDHL) has a recorded net income of $23.92 M.RedHill Biopharma Ltd. has generated $4 earnings per share over the last four quarters.
RedHill Biopharma Ltd. (:RDHL) has a price-to-earnings ratio of 0 and price/earnings-to-growth ratio is 0.